Kristian Reich, Chief Scientific Officer at MoonLake Immunotherapeutics (MLTX), sold 50,000 shares at $60.15 ($3.1M) on 2024-02-16, disclosed to the SEC on 2024-02-16.
Scheduled sale ($3.1M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.42 | 10,000 | $624K | 20.4% |
| 2 | $62.43 | 10,000 | $624K | 20.4% |
| 3 | $60.16 | 10,000 | $602K | 19.7% |
| 4 | $60.17 | 10,000 | $602K | 19.7% |
| 5 | $60.15 | 10,000 | $602K | 19.7% |
| Total | $61.07 avg | 50,000 |
| $3.1M |
| 100% |
| Filing → |
| MLTX | SELL | 2026-07-21 | $878K | — | Filing → |
| MLTX | SELL | 2026-07-20 | $322K | — | Filing → |
| MLTX | SELL | 2026-06-17 | $2.9M | — | Filing → |